Published in
Nature Research, Nature Communications, 1(13), 2022
DOI: 10.1038/s41467-022-32263-7
Links
Tools
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
,
Alessandro Cozzi Lepri,
Alessandro Cozzi Lepri,
Stefania Cicalini,
Giulia Matusali,
Veronica Bordoni,
Simone Lanini,
Silvia Meschi,
Roberta Iannazzo,
Valentina Mazzotta,
Francesca Colavita,
Ilaria Mastrorosa,
Eleonora Cimini,
Davide Mariotti,
Lydia De Pascale
and other authors.
Full text: Download
Abstract
AbstractIn order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm3 and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm3 (20–122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log2 difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.